Controversial Link between Cannabis and Anticancer Treatments-Where Are We and Where Are We Going? A Systematic Review of the Literature.
cancer
cannabidiol
cannabis
dronabinol
endocannabinoids
medical marijuana
nabilone
nabiximols
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Aug 2022
22 Aug 2022
Historique:
received:
12
07
2022
revised:
18
08
2022
accepted:
19
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Cannabinoids are currently used in cancer patients primarily for their pain-relieving and antiemetic properties. The aim of our review was to synthesize all available data of studies evaluating the therapeutic efficacy of cannabis in combination with oncological treatments in cancer patients and to explore ongoing studies with different goals and medical areas registered in the field of oncology worldwide. This study was performed in accordance with the PRISMA guidelines. A search using MEDLINE/PubMed database was performed between 1 January 2006 and 1 March 2022. Search terms included the following: cannabidiol, cannabis, CBD, dronabinol, endocannabinoids, medical marijuana, nabiximols, nabilone, THC, and cancer. All studies that examined the efficacy of cannabis administered during oncological treatments, regardless of cancer localization, subtype, and sample size, were considered eligible. In three studies, cannabis was administered to patients with glioblastoma, and in two other studies, cannabis was used in combination with immunotherapy in various cancer subgroups. The results of the clinical trials in cancer patients are not sufficient to draw conclusions at this time. Interestingly, several other studies addressing the systemic effects of cannabinoids in cancer patients are currently listed in the U.S. National Library of Medicine's registry on the ClinicalTrials.gov website. However, only one of the registered studies examined the efficacy of cannabinoids as a potential option for systemic cancer treatment. Although cannabis is touted to the public as a cancer cure, clinical trials need to clarify which combinations of chemotherapeutic agents with cannabinoids are useful for cancer patients.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Cannabinoids are currently used in cancer patients primarily for their pain-relieving and antiemetic properties. The aim of our review was to synthesize all available data of studies evaluating the therapeutic efficacy of cannabis in combination with oncological treatments in cancer patients and to explore ongoing studies with different goals and medical areas registered in the field of oncology worldwide.
MATERIALS AND METHODS
METHODS
This study was performed in accordance with the PRISMA guidelines. A search using MEDLINE/PubMed database was performed between 1 January 2006 and 1 March 2022. Search terms included the following: cannabidiol, cannabis, CBD, dronabinol, endocannabinoids, medical marijuana, nabiximols, nabilone, THC, and cancer. All studies that examined the efficacy of cannabis administered during oncological treatments, regardless of cancer localization, subtype, and sample size, were considered eligible.
RESULTS
RESULTS
In three studies, cannabis was administered to patients with glioblastoma, and in two other studies, cannabis was used in combination with immunotherapy in various cancer subgroups. The results of the clinical trials in cancer patients are not sufficient to draw conclusions at this time. Interestingly, several other studies addressing the systemic effects of cannabinoids in cancer patients are currently listed in the U.S. National Library of Medicine's registry on the ClinicalTrials.gov website. However, only one of the registered studies examined the efficacy of cannabinoids as a potential option for systemic cancer treatment.
CONCLUSIONS
CONCLUSIONS
Although cannabis is touted to the public as a cancer cure, clinical trials need to clarify which combinations of chemotherapeutic agents with cannabinoids are useful for cancer patients.
Identifiants
pubmed: 36011049
pii: cancers14164057
doi: 10.3390/cancers14164057
pmc: PMC9406903
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Cell Death Differ. 2011 Jul;18(7):1099-111
pubmed: 21475304
Clin Cancer Res. 2009 Jan 15;15(2):425-30
pubmed: 19147746
Oncologist. 2019 Apr;24(4):549-554
pubmed: 30670598
Ann Pharm Fr. 2008 Aug;66(4):219-31
pubmed: 18847570
Front Med (Lausanne). 2021 Sep 24;8:713153
pubmed: 34631734
Nature. 2018 Mar 15;555(7696):371-376
pubmed: 29489755
Lung India. 2014 Oct;31(4):431-2
pubmed: 25378867
Proc Soc Exp Biol Med. 2000 Oct;225(1):1-8
pubmed: 10998193
Cancer Causes Control. 2006 Jun;17(5):663-9
pubmed: 16633913
Dtsch Arztebl Int. 2012 Jul;109(29-30):495-501
pubmed: 23008748
Pharmacol Biochem Behav. 1991 Nov;40(3):691-4
pubmed: 1666929
J Clin Oncol. 2018 Jul 1;36(19):1957-1962
pubmed: 29746226
PLoS One. 2013 Oct 21;8(10):e76918
pubmed: 24204703
J Cancer Res Clin Oncol. 2021 Sep;147(9):2507-2534
pubmed: 34259916
Med Cannabis Cannabinoids. 2019 May 24;2(1):14-21
pubmed: 34676329
Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1644-1652
pubmed: 29093004
Br J Pharmacol. 2008 Jan;153(2):199-215
pubmed: 17828291
Cureus. 2019 Jan 19;11(1):e3918
pubmed: 30931189
Future Med Chem. 2009 Oct;1(7):1333-49
pubmed: 20191092
Cancer. 2011 Feb 15;117(4):848-53
pubmed: 20925043
J Natl Cancer Inst. 1975 Sep;55(3):597-602
pubmed: 1159836
Cancer. 1989 May 15;63(10):1904-11
pubmed: 2649219
Arch Esp Urol. 2001 Mar;54(2):165-7
pubmed: 11341122
Iran J Psychiatry. 2012 Fall;7(4):149-56
pubmed: 23408483
Lancet. 1998 Nov 14;352(9140):1611-6
pubmed: 9843121
Drugs. 2000 Dec;60(6):1303-14
pubmed: 11152013
J Thorac Oncol. 2008 Dec;3(12):1398-403
pubmed: 19057263
Biol Psychiatry. 2016 Apr 1;79(7):516-25
pubmed: 26698193
J Neurooncol. 2004 May;68(1):57-69
pubmed: 15174522
J Natl Cancer Inst Monogr. 2021 Nov 28;2021(58):86-98
pubmed: 34850897
Cancers (Basel). 2020 Aug 28;12(9):
pubmed: 32872248
Br J Cancer. 2021 Apr;124(8):1379-1387
pubmed: 33623076
Acta Pharm Sin B. 2015 Sep;5(5):402-18
pubmed: 26579471
Br J Pharmacol. 2003 Oct;140(3):547-57
pubmed: 14522843
J Pain Symptom Manage. 2013 Aug;46(2):207-18
pubmed: 23141881
Nat Rev Neurosci. 2007 Nov;8(11):885-95
pubmed: 17925811
Cancer. 2012 Nov 1;118(21):5374-83
pubmed: 22965656
Indian J Urol. 2012 Jan;28(1):9-14
pubmed: 22557710
Front Oncol. 2021 May 21;11:649555
pubmed: 34094937
Acta Oncol. 2008;47(6):1062-70
pubmed: 17934890
BMJ Support Palliat Care. 2020 Mar;10(1):14-24
pubmed: 31959586
J Thorac Oncol. 2006 Jul;1(6):577-9
pubmed: 17409920
Chem Biodivers. 2007 Aug;4(8):1664-77
pubmed: 17712813
Urology. 2006 Jan;67(1):100-4
pubmed: 16413342
Br J Pharmacol. 2008 Jan;153(2):319-34
pubmed: 17994113
Int J Oncol. 2012 Aug;41(2):407-13
pubmed: 22614735
J Clin Med. 2019 Jul 19;8(7):
pubmed: 31330972
Cancer Res. 2006 Jul 1;66(13):6615-21
pubmed: 16818634
Indian J Physiol Pharmacol. 2008 Jul-Sep;52(3):217-32
pubmed: 19552052
Int J Environ Res Public Health. 2019 Oct 28;16(21):
pubmed: 31661851
Oncotarget. 2020 Mar 31;11(13):1141-1156
pubmed: 32284791
Cell Death Dis. 2019 Nov 7;10(11):846
pubmed: 31699976
CNS Neurol Disord Drug Targets. 2009 Dec;8(6):403-21
pubmed: 19839937
Br J Cancer. 2006 Jul 17;95(2):197-203
pubmed: 16804518
Cancer Epidemiol Biomarkers Prev. 1999 Dec;8(12):1071-8
pubmed: 10613339
Front Pharmacol. 2017 Mar 24;8:144
pubmed: 28392768
Int J Environ Res Public Health. 2019 Aug 26;16(17):
pubmed: 31454942
Eur Respir J. 2008 Feb;31(2):280-6
pubmed: 18238947
Pharmacol Res. 2021 Jan;163:105302
pubmed: 33246167
Nature. 2018 Mar 15;555(7696):321-327
pubmed: 29489754
Int Psychogeriatr. 2011 Jun;23(5):732-41
pubmed: 21108863
Cancer Causes Control. 1997 Sep;8(5):722-8
pubmed: 9328194
Neuropharmacology. 2018 Jun;135:22-33
pubmed: 29510186
Immunobiology. 2010 Aug;215(8):598-605
pubmed: 19457575
Anticancer Res. 2011 Nov;31(11):3799-807
pubmed: 22110202
BMC Complement Altern Med. 2016 Sep 01;16(1):335
pubmed: 27586579
J Neuroimmune Pharmacol. 2018 Dec;13(4):438-452
pubmed: 29556883
Ann Pharmacother. 2021 Jul;55(7):870-890
pubmed: 33070617
Curr Pharm Des. 2012;18(32):4966-79
pubmed: 22716148
Urology. 2006 Jan;67(1):200
pubmed: 16413373
Cell Death Dis. 2013 Jun 13;4:e664
pubmed: 23764845
Br J Pharmacol. 2006 May;148(2):123-35
pubmed: 16501583
Cannabis Cannabinoid Res. 2022 Feb;7(1):24-33
pubmed: 34370591
Alcohol. 2005 Apr;35(3):265-75
pubmed: 16054989
Cancer. 2017 Nov 15;123(22):4488-4497
pubmed: 28944449
Br J Pharmacol. 2016 Jun;173(12):1899-910
pubmed: 27077495
Curr Pharm Des. 2012;18(32):5131-40
pubmed: 22716160
Cancer Res. 2008 Mar 15;68(6):1945-52
pubmed: 18339876
Cannabis Cannabinoid Res. 2018 Oct 01;3(1):195-202
pubmed: 30426072
Cancer. 2009 Mar 15;115(6):1215-23
pubmed: 19204904
J Clin Pharmacol. 2002 Nov;42(S1):103S-107S
pubmed: 12412843
Curr Opin Support Palliat Care. 2020 Jun;14(2):87-93
pubmed: 32332209